organization · Reporting owner

H.I.G.-GPII, Inc.

Disclosed activity across 4 companies

Tapewire entity: 128784
SEC CIK: 0001788482

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Clarus Therapeutics Holdings, Inc.CRXT · Entity 126356	10% owner	September 09, 2021	October 04, 2021
EXAGEN INC.XGN · Entity 935	10% owner	September 23, 2019	September 23, 2019
Lulu's Fashion Lounge Holdings, Inc.LVLU · Entity 7397	10% owner	November 10, 2021	November 11, 2021
eHealth, Inc.EHTH · Entity 497	10% owner	September 10, 2021	March 25, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Clarus Therapeutics Holdings, Inc.

Report date September 09, 2021 · Filed October 04, 2021

Jointly reported with H.I.G. Ventures - Clarus, LLC, H.I.G. Bio-Clarus II, L.P., H.I.G. Bio-Clarus I, L.P., TAMER ANTHONY, MNAYMNEH SAMI

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	490,531	Reported balance After 2021-09-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-09-09 · Grant · Acquired 490,531 · Balance 490,531 F1: Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer. F2: The shares reported are held of record by H.I.G. Bio -- Clarus I, L.P ("Clarus I"). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of Clarus I and has sole voting and investment control over the shares owned by Clarus I. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus I. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,731,094	Reported balance After 2021-09-09 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-09-09 · Grant · Acquired 2,731,094 · Balance 2,731,094 F1: Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer. F3: The shares reported are held of record by H.I.G. Ventures - Clarus, LLC ("H.I.G. Ventures"). H.I.G. GP is the manager of H.I.G. Ventures and has sole voting and investment control over the shares owned by H.I.G. Ventures. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Ventures. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,470,756	Reported balance After 2021-09-09 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-09-09 · Grant · Acquired 2,470,756 · Balance 2,470,756 F1: Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer. F4: The shares reported are held of record by H.I.G. Bio -- Clarus II, L.P ("Clarus II"). H.I.G. GP is the general partner of Clarus II and has sole voting and investment control over the shares owned by Clarus II. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus II. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer.

F2: The shares reported are held of record by H.I.G. Bio -- Clarus I, L.P ("Clarus I"). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of Clarus I and has sole voting and investment control over the shares owned by Clarus I. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus I. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.

F3: The shares reported are held of record by H.I.G. Ventures - Clarus, LLC ("H.I.G. Ventures"). H.I.G. GP is the manager of H.I.G. Ventures and has sole voting and investment control over the shares owned by H.I.G. Ventures. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Ventures. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.

F4: The shares reported are held of record by H.I.G. Bio -- Clarus II, L.P ("Clarus II"). H.I.G. GP is the general partner of Clarus II and has sole voting and investment control over the shares owned by Clarus II. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus II. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.

EXAGEN INC.

Report date September 23, 2019 · Filed September 23, 2019

Jointly reported with H.I.G. Bio-Exagen, L.P., TAMER ANTHONY, MNAYMNEH SAMI

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,696,252	Last balance in matching sequence After 2019-09-23 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2019-09-23 · Conversion · Acquired 1,271,252 · Balance 1,271,252 F1: The shares reported on this form are held of record by H.I.G. Bio-Exagen, L.P. ("H.I.G."). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of H.I.G. and has sole voting and investment control over the shares owned by H.I.G. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Bio-Exagen, L.P. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any. Row 2 · 2019-09-23 · Purchase · Acquired 425,000 · Balance 1,696,252 F1: The shares reported on this form are held of record by H.I.G. Bio-Exagen, L.P. ("H.I.G."). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of H.I.G. and has sole voting and investment control over the shares owned by H.I.G. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Bio-Exagen, L.P. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.
Series H Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2019-09-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-09-23 · Conversion · Disposed 233,446,519 · Balance 0 F2: The Series H Redeemable Convertible Preferred Stock ("Series H") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series H automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F1: The shares reported on this form are held of record by H.I.G. Bio-Exagen, L.P. ("H.I.G."). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of H.I.G. and has sole voting and investment control over the shares owned by H.I.G. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Bio-Exagen, L.P. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported on this form are held of record by H.I.G. Bio-Exagen, L.P. ("H.I.G."). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of H.I.G. and has sole voting and investment control over the shares owned by H.I.G. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Bio-Exagen, L.P. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.

F2: The Series H Redeemable Convertible Preferred Stock ("Series H") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series H automatically converted into Common Stock upon the closing of the Issuer's initial public offering.

Lulu's Fashion Lounge Holdings, Inc.

Report date November 10, 2021 · Filed November 11, 2021

Jointly reported with H.I.G. Growth Partners Lulu's, L.P., H.I.G. Growth Partners - Lulu's Intermediate, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,791,895	Reported balance Holding disclosure · report date 2021-11-10 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 13,791,895 F1: H.I.G.-GPII, Inc. is the sole general partner of H.I.G. Growth Partners - Lulu's, L.P., and has sole voting and dispositive power with respect to the shares held by H.I.G. Growth Partners - Lulu's, L.P. H.I.G.-GPII, Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Sami Mnaymneh and Anthony Tamer, the directors of H.I.G.-GPII, Inc., have shared voting and dispositive power with respect to the shares held by H.I.G. Growth Partners - Lulu's, L.P. Messrs. Mnaymneh and Tamer may be deemed to be indirect beneficial owners of the reported securities, but disclaim beneficial ownership in the securities, except to the extent of any pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: H.I.G.-GPII, Inc. is the sole general partner of H.I.G. Growth Partners - Lulu's, L.P., and has sole voting and dispositive power with respect to the shares held by H.I.G. Growth Partners - Lulu's, L.P. H.I.G.-GPII, Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Sami Mnaymneh and Anthony Tamer, the directors of H.I.G.-GPII, Inc., have shared voting and dispositive power with respect to the shares held by H.I.G. Growth Partners - Lulu's, L.P. Messrs. Mnaymneh and Tamer may be deemed to be indirect beneficial owners of the reported securities, but disclaim beneficial ownership in the securities, except to the extent of any pecuniary interest in such securities.

eHealth, Inc.

Report date September 10, 2021 · Filed March 25, 2022

Jointly reported with Echelon Health SPV, LP, Echelon Health SPV GP, LLC, H.I.G. Echelon, LP, H.I.G. Middle Market LBO Fund III, L.P., H.I.G. Middle Market Advisors III, LLC, MNAYMNEH SAMI, TAMER ANTHONY

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee Notes	Not disclosed	Reported balance Holding disclosure · report date 2021-09-10 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The Reporting Persons beneficially own 2,250,000 shares of the Issuer's Series A Preferred Stock (the "Series A Preferred Stock"). The Series A Preferred Stock provides for paid-in-kind ("PIK") dividends at an annual rate of 8%, which accrue daily and compound semi-annually. The Series A Preferred Stock became convertible into shares of the Issuer's common stock (the "Common Stock") on June 1, 2021. The number of shares of Common Stock issuable upon conversion of a share of Series A Preferred Stock equals (A) $100 plus PIK dividends calculated up to the most recent semi-annual dividend payment date plus PIK dividends accrued since the most recent semi-annual dividend payment date divided by (B) the conversion price of $79.5861, which is subject to adjustment upon the occurrence of certain specified events. F2: As of September 10, 2021, the Series A Preferred Stock beneficially owned by the Reporting Persons was convertible into 2,910,708.48 shares of Common Stock. As of March 25, 2022, the Series A Preferred Stock beneficially owned by the Reporting Persons was convertible into 3,035,822.97 shares of Common Stock. F3: The securities reported herein are held directly by Echelon Health SPV, LP ("Echelon LP"), Echelon Health SPV GP, LLC, a Delaware limited liability company ("Echelon GP"), is the general partner of Echelon LP. H.I.G. Echelon, LP, a Delaware limited partnership ("Holdco"), is the sole member of Echelon LP. H.I.G. Middle Market LBO Fund III, L.P., a Delaware limited partnership ("Middle Market LBO III"), is the controlling interest holder of Holdco and Echelon GP. H.I.G. Middle Market Advisors III, LLC, a Delaware limited liability company ("Middle Market Advisors III"), is the general partner of Middle Market LBO III and the manager of Echelon GP. H.I.G.-GPII, Inc., a Delaware corporation ("GPII" and together with Echelon LP, Echelon GP, Holdco, Middle Market LBO III and Middle Market Advisors III, the "HIG Funds"), is the general partner of Holdco and the manager of Middle Market Advisors III. F4: Sami W. Mnaymneh and Anthony A. Tamer are the sole shareholders of GPII. As a result of the foregoing relationships, each of the HIG Funds and Messrs. Mnaymneh and Tamer may be deemed to beneficially own the Series A Preferred Stock held by Echelon LP. Messrs. Mnaymneh and Tamer disclaim beneficial ownership of the shares held by the HIG Funds except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Persons beneficially own 2,250,000 shares of the Issuer's Series A Preferred Stock (the "Series A Preferred Stock"). The Series A Preferred Stock provides for paid-in-kind ("PIK") dividends at an annual rate of 8%, which accrue daily and compound semi-annually. The Series A Preferred Stock became convertible into shares of the Issuer's common stock (the "Common Stock") on June 1, 2021. The number of shares of Common Stock issuable upon conversion of a share of Series A Preferred Stock equals (A) $100 plus PIK dividends calculated up to the most recent semi-annual dividend payment date plus PIK dividends accrued since the most recent semi-annual dividend payment date divided by (B) the conversion price of $79.5861, which is subject to adjustment upon the occurrence of certain specified events.

F2: As of September 10, 2021, the Series A Preferred Stock beneficially owned by the Reporting Persons was convertible into 2,910,708.48 shares of Common Stock. As of March 25, 2022, the Series A Preferred Stock beneficially owned by the Reporting Persons was convertible into 3,035,822.97 shares of Common Stock.

F3: The securities reported herein are held directly by Echelon Health SPV, LP ("Echelon LP"), Echelon Health SPV GP, LLC, a Delaware limited liability company ("Echelon GP"), is the general partner of Echelon LP. H.I.G. Echelon, LP, a Delaware limited partnership ("Holdco"), is the sole member of Echelon LP. H.I.G. Middle Market LBO Fund III, L.P., a Delaware limited partnership ("Middle Market LBO III"), is the controlling interest holder of Holdco and Echelon GP. H.I.G. Middle Market Advisors III, LLC, a Delaware limited liability company ("Middle Market Advisors III"), is the general partner of Middle Market LBO III and the manager of Echelon GP. H.I.G.-GPII, Inc., a Delaware corporation ("GPII" and together with Echelon LP, Echelon GP, Holdco, Middle Market LBO III and Middle Market Advisors III, the "HIG Funds"), is the general partner of Holdco and the manager of Middle Market Advisors III.

F4: Sami W. Mnaymneh and Anthony A. Tamer are the sole shareholders of GPII. As a result of the foregoing relationships, each of the HIG Funds and Messrs. Mnaymneh and Tamer may be deemed to beneficially own the Series A Preferred Stock held by Echelon LP. Messrs. Mnaymneh and Tamer disclaim beneficial ownership of the shares held by the HIG Funds except to the extent of their pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 09, 2021 Filed Oct 4, 2021 16:09 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	GrantCommon Stock	2,470,756	$0.00	$0.00	Disclosure SEC source: 0001013762-21-000025 · ownership.xml · nonDerivative · entry 3 H.I.G. Ventures - Clarus, LLC · CIK 0001512060 · 10% owner H.I.G. Bio-Clarus II, L.P. · CIK 0001885010 · 10% owner H.I.G. Bio-Clarus I, L.P. · CIK 0001884997 · 10% owner H.I.G.-GPII, Inc. · CIK 0001788482 · 10% owner TAMER ANTHONY · CIK 0001050045 · 10% owner MNAYMNEH SAMI · CIK 0001050046 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,470,756 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer. F4 · ownership.nature: The shares reported are held of record by H.I.G. Bio -- Clarus II, L.P ("Clarus II"). H.I.G. GP is the general partner of Clarus II and has sole voting and investment control over the shares owned by Clarus II. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus II. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any. Read SEC document
September 09, 2021 Filed Oct 4, 2021 16:09 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	GrantCommon Stock	2,731,094	$0.00	$0.00	Disclosure SEC source: 0001013762-21-000025 · ownership.xml · nonDerivative · entry 2 H.I.G. Ventures - Clarus, LLC · CIK 0001512060 · 10% owner H.I.G. Bio-Clarus II, L.P. · CIK 0001885010 · 10% owner H.I.G. Bio-Clarus I, L.P. · CIK 0001884997 · 10% owner H.I.G.-GPII, Inc. · CIK 0001788482 · 10% owner TAMER ANTHONY · CIK 0001050045 · 10% owner MNAYMNEH SAMI · CIK 0001050046 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,731,094 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer. F3 · ownership.nature: The shares reported are held of record by H.I.G. Ventures - Clarus, LLC ("H.I.G. Ventures"). H.I.G. GP is the manager of H.I.G. Ventures and has sole voting and investment control over the shares owned by H.I.G. Ventures. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Ventures. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any. Read SEC document
September 09, 2021 Filed Oct 4, 2021 16:09 UTC	Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356	GrantCommon Stock	490,531	$0.00	$0.00	Disclosure SEC source: 0001013762-21-000025 · ownership.xml · nonDerivative · entry 1 H.I.G. Ventures - Clarus, LLC · CIK 0001512060 · 10% owner H.I.G. Bio-Clarus II, L.P. · CIK 0001885010 · 10% owner H.I.G. Bio-Clarus I, L.P. · CIK 0001884997 · 10% owner H.I.G.-GPII, Inc. · CIK 0001788482 · 10% owner TAMER ANTHONY · CIK 0001050045 · 10% owner MNAYMNEH SAMI · CIK 0001050046 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 490,531 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer. F2 · ownership.nature: The shares reported are held of record by H.I.G. Bio -- Clarus I, L.P ("Clarus I"). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of Clarus I and has sole voting and investment control over the shares owned by Clarus I. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus I. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any. Read SEC document
September 23, 2019 Filed Sep 23, 2019 21:43 UTC	EXAGEN INC. XGN · Entity 935	ConversionSeries H Redeemable Convertible Preferred Stock · Derivative	233,446,519	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-024078 · doc4.xml · derivative · entry 3 H.I.G. Bio-Exagen, L.P. · CIK 0001788396 · 10% owner H.I.G.-GPII, Inc. · CIK 0001788482 · 10% owner TAMER ANTHONY · CIK 0001050045 · 10% owner MNAYMNEH SAMI · CIK 0001050046 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,271,252 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series H Redeemable Convertible Preferred Stock ("Series H") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series H automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F2 · price: The Series H Redeemable Convertible Preferred Stock ("Series H") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series H automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F2 · derivative.exercise_date: The Series H Redeemable Convertible Preferred Stock ("Series H") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series H automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F2 · derivative.expiration_date: The Series H Redeemable Convertible Preferred Stock ("Series H") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series H automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The shares reported on this form are held of record by H.I.G. Bio-Exagen, L.P. ("H.I.G."). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of H.I.G. and has sole voting and investment control over the shares owned by H.I.G. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Bio-Exagen, L.P. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any. Read SEC document
September 23, 2019 Filed Sep 23, 2019 21:43 UTC	EXAGEN INC. XGN · Entity 935	PurchaseCommon Stock	425,000	$14.00	$5,950,000.00	Disclosure SEC source: 0000899243-19-024078 · doc4.xml · nonDerivative · entry 2 H.I.G. Bio-Exagen, L.P. · CIK 0001788396 · 10% owner H.I.G.-GPII, Inc. · CIK 0001788482 · 10% owner TAMER ANTHONY · CIK 0001050045 · 10% owner MNAYMNEH SAMI · CIK 0001050046 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,696,252 F1 · ownership.nature: The shares reported on this form are held of record by H.I.G. Bio-Exagen, L.P. ("H.I.G."). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of H.I.G. and has sole voting and investment control over the shares owned by H.I.G. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Bio-Exagen, L.P. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any. Read SEC document
September 23, 2019 Filed Sep 23, 2019 21:43 UTC	EXAGEN INC. XGN · Entity 935	ConversionCommon Stock	1,271,252	$0.00	$0.00	Disclosure SEC source: 0000899243-19-024078 · doc4.xml · nonDerivative · entry 1 H.I.G. Bio-Exagen, L.P. · CIK 0001788396 · 10% owner H.I.G.-GPII, Inc. · CIK 0001788482 · 10% owner TAMER ANTHONY · CIK 0001050045 · 10% owner MNAYMNEH SAMI · CIK 0001050046 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,271,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares reported on this form are held of record by H.I.G. Bio-Exagen, L.P. ("H.I.G."). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of H.I.G. and has sole voting and investment control over the shares owned by H.I.G. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Bio-Exagen, L.P. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.